©2024 Stanford Medicine
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Recruiting
I'm InterestedTrial ID: NCT04745234
Purpose
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of
mogamulizumab given Q4W following initial weekly induction in adult participants with
relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening
Period during which participants are screened for entry into this study, followed by a
treatment period of up to 2 years from Cycle 1 Day 1.
Official Title
Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants With Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
Stanford Investigator(s)
Youn H Kim, MD
The Joanne and Peter Haas, Jr., Professor for Cutaneous Lymphoma Research and Professor, by courtesy, of Medicine (Oncology)
Eligibility
Inclusion Criteria:
- Histologically confirmed diagnosis of MF or SS
- Stage IB, II-A, II-B, III, or IV;
- Participants who have failed at least one prior course of systemic therapy (e.g.,
interferon, bexarotene, photopheresis, anti-neoplastic chemotherapy). Psoralen plus
ultraviolet light therapy (PUVA) is not considered a systemic therapy.
Exclusion Criteria:
- Current evidence of large cell transformation;
- Prior treatment with mogamulizumab;
- History of allogeneic transplant.
Intervention(s):
drug: Mogamulizumab
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kumari Khushboo